Exelixis, Inc.
EXEL
#1571
Rank
$13.901 B
Marketcap
United States
Country
$56.10
Share price
9.29%
Change (1 day)
39.00%
Change (1 year)
Categories
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its…
Key Metrics
Trailing P/E
17.67
Forward P/E
13.35
EPS (TTM)
$3.22
Forward EPS
$4.26
Price / Book
7.68
EV / EBITDA
13.2x
Beta
0.42
Dividend Yield
—
Return on Equity
44.39%
Return on Assets
23.97%
Debt / Equity
9.00
Current Ratio
3.46
Gross Margin
96.48%
Operating Margin
39.51%
Net Profit Margin
35.33%
Free Cash Flow
$739.715M
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 17 – Sep 15
+8.75%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$2.320B
Latest Net Income$782.570M
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Exelixis, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
EXEL
No recent news available. Set FINNHUB_API_KEY to enable news.
